|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||79.40 - 81.80|
|52-week range||29.90 - 87.10|
|PE ratio (TTM)||N/A|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||75.60|
Foundation Medicine, Inc. today announced that the Centers for Medicare & Medicaid Services issued a final National Coverage Determination for patients who receive next generation sequencing testing with an assay that meets the coverage criteria.
Foundation Medicine, Inc. today announced that Chugai Pharmaceutical Co., Ltd. , one of Japan's leading research-based pharmaceutical companies and a member of the Roche Group, will broaden patient access to Foundation Medicine’s comprehensive genomic profiling services for individuals with advanced cancer.
Foundation Medicine, Inc. and Guardant Health, Inc. announced an agreement to settle false advertising challenges that the companies had filed against each other under the Lanham Act related to advertising for their respective liquid genomic profiling assays.
Foundation Medicine, Inc. today announced that members of the company's management team will present at Cowen & Company’s 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 10:40 a.m.
The Cambridge, Massachusetts-based company said it had a loss of $1.05 per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Foundation Medicine today reported financial and operational results for the fourth quarter and year ended December 31, 2017. Highlights for the quarter and year inclu
Foundation Medicine, Inc. today announced that financial results for the company's fourth quarter and year ended December 31, 2017 will be released on Wednesday, March 7, 2018.
Foundation Medicine, Inc. and the European Organisation for Research and Treatment of Cancer announced today a collaboration in which Foundation Medicine’s comprehensive genomic profiling tests will be used to inform patient eligibility for oncology clinical trials through the EORTC’s Screening Patients for Efficient Clinical Trial Access program.
NEW YORK, Jan. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lands' ...
Foundation Medicine, Inc. today announced that the company has entered into a broad partnership with Pfizer Inc. . The partnership focuses on development, regulatory support and commercialization of companion diagnostics that will be included in updates to FoundationOne CDx™.
Foundation Medicine today announced preliminary unaudited total revenue of approximately $48.9 million for the fourth quarter of 2017 and approximately $152.9 million for the full year ended December 31, 2017, representing a 70% and 31% increase from the $28.8 million and $116.9 million recorded in the fourth quarter and full year ended December 31, 2016, respectively.
Foundation Medicine today announced that Troy Cox, chief executive officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 3:30 p.m.
Foundation Medicine, Inc. today announced that new data generated with FoundationOne®Heme, its comprehensive genomic profiling assay for hematologic malignancies and sarcomas, will be presented at the American Society of Hematology Annual Meeting.
Determining which cancer drugs will work best in each individual patient could become easier following this important FDA approval.
Foundation Medicine hit a high after U.S. regulators approved its test to match cancer patients to FDA-approved therapies.
Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration approved FoundationOne CDx™, the company’s comprehensive companion diagnostic test for solid tumors.
Investors in Foundation Medicine (FMI) need to pay close attention to the stock based on moves in the options market lately.